Stephen Hauser
Internal Medicine · San Francisco, CANPI 1700996931
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 59.4% of the total. Reporting peaked in 2019 at $42,169 and has fallen 73.3% since, to $11,268 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $850.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$43K
- Novartis Pharma AG$11K
- Genentech, Inc.$9K
- Modernatx, Inc.$4K
- Gilead$3K
- BD$2K
- plus $485 from 5 others
Across 102 payments — averaging $1322.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$126K
- Novartis Pharma AG$6K
- Novartis$2K
What the payments were for
- Consulting fees$9,28913%
- Speaking & faculty fees$33,17046%
- Travel & lodging$29,02140%
- Food & beverage$8511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 53 | $42,994 |
| Novartis Pharma AG | 9 | $11,205 |
| Genentech, Inc. | 10 | $9,146 |
| Modernatx, Inc. | 2 | $4,000 |
| Gilead | 1 | $3,000 |
| BD | 1 | $1,500 |
| Genentech USA, Inc. | 4 | $193 |
| Biomarin Pharmaceutical Inc. | 1 | $81 |
| Roche Products Limited | 2 | $77 |
| Leica Microsystems Inc. | 1 | $71 |
| Novartis | 1 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,330 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 17 | $2,060 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.